Overview
One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Indication
For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma
Associated Conditions
- Acute angle-closure glaucoma
- Edema
- Familial periodic paralysis
- Generalized Tonic-Clonic Seizures
- Metabolic Alkalosis
- Open Angle Glaucoma (OAG)
- Other and unspecified effects of high altitude
- Cystine renal calculi
- Drug-induced edema
- Nonuveitic secondary glaucoma
- Salicylate intoxication
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/20 | Phase 2 | Recruiting | |||
2025/04/25 | Not Applicable | Not yet recruiting | |||
2025/01/15 | Phase 2 | Recruiting | Shionogi Apnimed Sleep Science | ||
2024/08/02 | Phase 3 | Recruiting | |||
2024/07/26 | Phase 2 | Recruiting | Sanjay R Patel | ||
2024/07/12 | Phase 4 | Recruiting | |||
2024/07/12 | Phase 4 | Recruiting | |||
2024/07/12 | Phase 4 | Recruiting | |||
2024/06/26 | Phase 4 | Recruiting | |||
2024/05/16 | Phase 4 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| A-S Medication Solutions | 50090-3132 | ORAL | 500 mg in 1 1 | 6/23/2020 | |
| A-S Medication Solutions | 50090-3003 | ORAL | 250 mg in 1 1 | 1/22/2020 | |
| Zydus Lifesciences Limited | 65841-762 | ORAL | 500 mg in 1 1 | 2/22/2024 | |
| Zydus Pharmaceuticals (USA) Inc. | 70710-1238 | ORAL | 125 mg in 1 1 | 3/26/2024 | |
| ANI Pharmaceuticals, Inc. | 70954-033 | ORAL | 125 mg in 1 1 | 3/22/2023 | |
| Ajanta Pharma USA Inc. | 27241-133 | ORAL | 250 mg in 1 1 | 8/11/2023 | |
| Bryant Ranch Prepack | 63629-1194 | ORAL | 125 mg in 1 1 | 5/19/2023 | |
| Taro Pharmaceuticals U.S.A., Inc. | 51672-4023 | ORAL | 250 mg in 1 1 | 9/6/2016 | |
| Taro Pharmaceuticals U.S.A., Inc. | 51672-4022 | ORAL | 125 mg in 1 1 | 9/6/2016 | |
| Alembic Pharmaceuticals Inc. | 62332-349 | ORAL | 500 mg in 1 1 | 6/13/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| GP-ACETAZOLAMIDE TABLET 250MG | SIN16860P | TABLET | 250 mg | 9/13/2023 | |
| AA PHARMA ACETAZOLAMIDE TABLET 250 mg | SIN01140P | TABLET | 250 mg | 5/13/1988 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Diamox Tablet | 15204 | Medicine | A | 9/9/1991 | |
| GLAUMOX acetazolamide (as sodium) 500 mg powder for injection vial | 142075 | Medicine | A | 6/1/2009 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| ACETAZOLAMIDE | aa pharma inc | 00545015 | Tablet - Oral | 250 MG | 12/31/1982 |
| ACETAZOLAM | valeant canada lp / valeant canada s.e.c. | 00295019 | Tablet - Oral | 250 MG | 12/31/1974 |
| DIAMOX TABLETS 250MG | wyeth-ayerst canada inc. | 02238072 | Tablet - Oral | 250 MG | 10/27/1999 |
| DIAMOX TAB 250MG | storz, division of wyeth-ayerst canada inc. | 02039222 | Tablet - Oral | 250 MG | 12/31/1994 |
| DIAMOX SEQUELS | wyeth canada | 02238073 | Capsule (Sustained-Release) - Oral | 500 MG | 12/23/1998 |
| NOVO-ZOLAMIDE TAB 250MG | novopharm limited | 00488275 | Tablet - Oral | 250 MG | 12/31/1981 |
| DIAMOX SRC 500MG | storz, division of wyeth-ayerst canada inc. | 02039230 | Capsule (Sustained-Release) - Oral | 500 MG / SRC | 12/31/1994 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.